Citation

Judith Silverstein Currier, M.D., M.Sc., Paige L. Williams, Ph.D., Susan L. Koletar, M.D., Susan Ellen Cohn, M.D., M.P.H., Robert L. Murphy, M.D., Alison Heald, M.D., Richard Hafner, M.D., Ehab Bassily, M.Sc., Howard M. Lederman, M.D., Ph.D., Charles Knirsch, M.D., M.P.H., Constance A. Benson, M.D., Hernan Valdez, M.D., Judith A. Aberg, M.D., J. Allen McCutchan, M.D., M.Sc. Discontinuation of mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team. Annals of Internal Medicine. 2000 Oct 03; 133(7):493-503.

Citation

Mark A. Winters, M.S., Kristi L. Coolley, Peng Cheng, Yvette A. Girard, Hasnah Hamdan, Ladislau C. Kovari, Thomas C. Merigan, Jr., M.D. Genotypic, phenotypic, and modeling studies of a deletion in the beta3-beta4 region of the human immunodeficiency virus type 1 reverse transcriptase gene that is associated with resistance to nucleoside reverse transcriptase inhibitors. Journal of Virology. 2000 Nov 01; 74(22):10707-13.

Citation

J. Robins, Dianne M. Finkelstein, Ph.D. Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics. 2000 Sep 01; 56(3):779-88.

Citation

Charles Raines, C.R.N.P., M.S.N, Charles Flexner, M.D., Eugene Sun, M.D., Margo E. Heath-Chiozzi, M.D., Ronald Lewis, M.D., Catherine Fields, C. Deetz, Linda Apuzzo, B.S., C.C.R.C., Susan H. Eshleman, M.D., PH.D., Brooks Jackson, M.D., M.B.A., Joel E. Gallant, M.D., M.P.H. Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks. Journal of Acquired Immune Deficiency Syndromes. 2000 Dec 01; 25(4):322-8.

Citation

Leock Y. Ngo, Ram Yogev, Wayne M. Dankner, Walter T. Hughes, Sandra Burchett, Jing Xu, Brian Sadler, Jashvant D. Unadkat. Pharmacokinetics of Azithromycin Administered Alone and with Atovaquone in Human Immunodeficiency Virus-Infected Children. Antimicrobial Agents and Chemotherapy. 1999 Jun 01; 43(6):1516-19.

Citation

Mark W. Kline, M.D., Russell B. Van Dyke, M.D., Jane C. Lindsey, Sc.D., Meg Gwynne, B.A., Mary Culnane, C.R.N.P., M.S., Clemente Diaz, M.D., Ram Yogev, M.D., Ross E. McKinney, Jr., M.D., Elaine J. Abrams, M.D., Lynne M. Mofenson, M.D., F.A.A.P. Combination Therapy with Stavudine (d4T) Plus Didanosine (ddI) In Children With Human Immunodeficiency Virus Infection. Pediatrics. 1999 May 01; 103(5):e62.

Citation

William T. Shearer, M.D., Ph.D., Mark W. Kline, M.D., Stuart L. Abramson, M.D., Ph.D., Terence Fenton, Ed.D., Stuart E. Starr, M.D., Steven D. Douglas, M.D. Phase I/II Study of Recombinant Human Interferon-gamma (rIFN-gamma) in HIV-infected Children: Safety, CD4+ Lymphocyte Count, Viral Load, and Neutrophil Function (AIDS Clinical Trials Group Protocol 211). Clinical and Diagnostic Laboratory Immunology. 1999 May 01; 6(3):311-15.

Citation

Stevens RC, Frenkel LM, Rodman JH. Influence Of Age and Food On Didanosine Pharmacokinetics In HIV Infected Children. Pharmacotherapy. 1999 Nov 30; 19:487.

Citation

Shapiro DE, Sperling RS, Coombs RW. Effect Of Zidovudine On Perinatal HIV-1 Transmission and Maternal Viral Load (Letter). Lancet. 1999 Jul 10; 354(9173):156.